Mushroom-Derived Compounds as Metabolic Modulators in Cancer
Molecules · 02.02.2023 · 28 (3) · 1441
DOI: 10.3390/molecules28031441 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 02.02.2023. Verfasst von Bhoomika Dowaraka-Persad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biopharmaceutical Unit, Centre for Biomedical and Biomaterials Research (CBBR), University of Mauritius, Réduit 80837, Mauritius. Hauptthemen laut MEDLINE: Agaricales, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is responsible for lifelong disability and decreased quality of life. Cancer-associated changes in metabolism, in particular carbohydrate, lipid, and protein, offer a new paradigm of metabolic hits. Hence, targeting the latter, as well as related cross-linked signalling pathways, can reverse the malignant phenotype of transformed cells. The systemic toxicity and pharmacokinetic limitations of existing drugs prompt the discovery of multi-targeted and safe compounds from natural products. Mushrooms possess biological activities relevant to disease-fighting and to the prevention of cancer. They have a long-standing tradition of use in ethnomedicine and have been included as an adjunct therapy during and after oncological care. Mushroom-derived compounds have also been reported to target the key signature of cancer cells in in vitro and in vivo studies. The identification of metabolic pathways whose inhibition selectively affects cancer cells appears as an interesting approach to halting cell proliferation. For instance, panepoxydone exerted protective mechanisms against breast cancer initiation and progression by suppressing lactate dehydrogenase A expression levels and reinducing lactate dehydrogenase B expression levels. This further led to the accumulation of pyruvate, the activation of the electron transport chain, and increased levels of reactive oxygen species, which eventually triggered mitochondrial apoptosis in the breast cancer cells. Furthermore, the inhibition of hexokinase 2 by neoalbaconol induced selective cytotoxicity against nasopharyngeal carcinoma cell lines, and these effects were also observed in mouse models. Finally, GL22 inhibited hepatic tumour growth by downregulating the mRNA levels of fatty acid-binding proteins and blocking fatty acid transport and impairing cardiolipin biosynthesis. The present review, therefore, will highlight how the metabolites isolated from mushrooms can target potential biomarkers in metabolic reprogramming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biopharmaceutical Unit, Centre for Biomedical and Biomaterials Research (CBBR), University of Mauritius, Réduit 80837, Mauritius.
- Department of Health Sciences, Faculty of Medicine and Health Sciences, University of Mauritius, Réduit 80837, Mauritius.
Zitieren
APA
Dowaraka-Persad, B., & Neergheen, V. S. (2023). Mushroom-Derived Compounds as Metabolic Modulators in Cancer. Molecules, 28(3), 1441. https://doi.org/10.3390/molecules28031441
Vancouver
Dowaraka-Persad B, Neergheen VS. Mushroom-Derived Compounds as Metabolic Modulators in Cancer. Molecules. 2023;28(3):1441. doi:10.3390/molecules28031441
BibTeX
@article{DowarakaPersad2023,
author = {Dowaraka-Persad, Bhoomika and Neergheen, Vidushi Shradha},
title = {Mushroom-Derived Compounds as Metabolic Modulators in Cancer},
journal = {Molecules},
year = {2023},
volume = {28},
number = {3},
pages = {1441},
doi = {10.3390/molecules28031441}
}
EUVIMED